Quantum BioPharma reports doubled cash position, reduced burn rate

Quantum BioPharma Ltd. (NASDAQ: QNTM) reported its cash and cash equivalents combined with digital assets totaled $9.8 million as of March 31, 2026, more than doubling from $4.1 million at the end of 2025. The company stated this liquidity is sufficient to fund planned operations through approximately July 2027.

The biopharmaceutical company reduced cash used in operating activities by 60% to $1.66 million during the first quarter compared to the same period in 2025. The company attributed the decrease primarily to reduced research and development fees following completion of Phase 1 clinical trials.

Quantum submitted an Investigational New Drug application to the U.S. Food and Drug Administration for Lucid-MS, its drug candidate for treating multiple sclerosis. The company appointed Dr. Salvatore Napoli as principal investigator for the planned Phase 2 clinical trial and entered a binding letter of intent with Allucent, a contract research organization, to conduct the trial.

The company's cryptocurrency portfolio had a fair market value of $6.5 million as of the press release date, bringing total cash and cash equivalents to $11.2 million. Operating expenses decreased 13% during the quarter.

In legal proceedings, a U.S. District Court in New York denied a joint motion to dismiss filed by CIBC World Markets and RBC Dominion Securities in Quantum's lawsuit alleging market manipulation.

Quantum's subsidiary Unbuzzd completed a corporate reorganization and hired Richard Buzbuzian as chief executive officer to lead an initial public offering and nationwide commercialization efforts. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026.

The company entered a six-month corporate communications agreement with InvestorBrandNetwork for $77,400, according to the press release.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Uranium Royalty Corp. sets shareholder vote on $1.14B Sweetwater deal
• SEGG Media sues short seller for $20M over stock report